Moleculin Biotech's Q1 2025 earnings call highlights Phase 3 MIRACLE trial progress, EU regulatory signoff, patient enrollment milestones, and funding needs.

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences. Luellen shared the company's ambitious mission ...